All AbMole products are for research use only, cannot be used for human consumption.
Denintuzumab-MMAF is an antibody-drug conjugate (ADC). Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used in the research of acute lymphoblastic leukemia.
Immobilized human EGFR His at 2 ug/mL can bind denintuzumab-MMAF, the EC50 is 0.01985 ug/mL.
| Solubility (25°C) | For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. |
| Storage | Store at ≤ -20℃ for up to 24 months. Avoid repeated freeze-thaw cycles. |
| Related Antibody-Drug Conjugates (ADCs) Products |
|---|
| Lorvotuzumab-MMAE
Lorvotuzumab-MMAE is an antibody-drug conjugate (ADC). |
| Anetumab-MMAE
Anetumab-MMAE is an antibody-drug conjugate (ADC). |
| Praluzatamab-MMAE
Praluzatamab-MMAE is an antibody-drug conjugate (ADC). |
| Oregovomab-MMAE
Oregovomab-MMAE is an antibody-drug conjugate (ADC). |
| Patritumab-MMAE
Patritumab-MMAE is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab attached to MMAE. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
